| Symbol | ALGS |
|---|---|
| Name | ALIGOS THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | ONE CORPORATE DR.,2ND FLOOR, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 800 - 466-6059 |
| Fax | — |
| — | |
| Website | https://www.aligos.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001799448 |
| Description | Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The companys pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. Additional info from NASDAQ: |
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
Read moreAligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Read morePreston Heather 🟢 acquired 5.9K shares (1 derivative) of Aligos Therapeutics, Inc. (ALGS) at $5.50 Transaction Date: Jun 25, 2026 | Filing ID: 000305
Read moreChavez Margarita 🟢 acquired 5.9K shares (1 derivative) of Aligos Therapeutics, Inc. (ALGS) at $5.50 Transaction Date: Jun 25, 2026 | Filing ID: 000304
Read moreMartell Bridget A 🟢 acquired 5.9K shares (1 derivative) of Aligos Therapeutics, Inc. (ALGS) at $5.50 Transaction Date: Jun 25, 2026 | Filing ID: 000303
Read moreScopa James Paul 🟢 acquired 5.9K shares (1 derivative) of Aligos Therapeutics, Inc. (ALGS) at $5.50 Transaction Date: Jun 25, 2026 | Filing ID: 000302
Read moreNuechterlein Carole 🟢 acquired 5.9K shares (1 derivative) of Aligos Therapeutics, Inc. (ALGS) at $5.50 Transaction Date: Jun 25, 2026 | Filing ID: 000301
Read moreHirth Peter 🟢 acquired 5.9K shares (1 derivative) of Aligos Therapeutics, Inc. (ALGS) at $5.50 Transaction Date: Jun 25, 2026 | Filing ID: 000300
Read moreNew Form SCHEDULE 13G/A - Aligos Therapeutics, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000919574-26-003231 <b>Size:</b> 9 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07342881 | Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of … | Phase1 | Chronic Hepatitis B Infection | Completed | 2026-03-10 | 2026-07-29 | ClinicalTrials.gov |
| NCT07342868 | Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of… | Phase1 | Chronic Hepatitis B Infections | Completed | 2026-01-30 | 2026-08-19 | ClinicalTrials.gov |
| NCT06963710 | A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovi… | Phase2 | Chronic Hepatitis B Infection | Active_Not_Recruiting | 2025-07-15 | 2028-08-01 | ClinicalTrials.gov |
| NCT06959888 | A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability … | Phase1 | Healthy Volunteer Study | Completed | 2025-03-25 | 2025-05-16 | ClinicalTrials.gov |
| NCT06698549 | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558… | Phase1 | COVID 19 | Completed | 2025-02-20 | 2025-08-13 | ClinicalTrials.gov |
| NCT06568861 | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558… | Phase1 | COVID-19 | Completed | 2025-01-13 | 2025-07-28 | ClinicalTrials.gov |
| NCT06672900 | A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokine… | Phase1 | Healthy Volunteer | Active_Not_Recruiting | 2025-01-09 | 2025-07-07 | ClinicalTrials.gov |
| NCT06342947 | ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) | Phase2 | NASH | Completed | 2024-04-01 | 2024-09-09 | ClinicalTrials.gov |
| NCT06191991 | A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055… | Phase1 | Healthy Volunteers | Completed | 2023-11-03 | 2023-12-04 | ClinicalTrials.gov |
| NCT05840952 | A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the… | Phase1 | COVID-19 | Completed | 2023-07-04 | 2024-04-29 | ClinicalTrials.gov |
| NCT05561530 | A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and P… | Phase1 | Chronic Hepatitis B | Terminated | 2022-10-07 | 2023-06-15 | ClinicalTrials.gov |
| NCT05090111 | A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia | Phase1 | NASH - Nonalcoholic Steatohepatitis | Completed | 2021-12-01 | 2023-06-16 | ClinicalTrials.gov |
| NCT05001022 | A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics a… | Phase1 | Chronic Hepatitis B | Terminated | 2021-09-25 | 2022-07-18 | ClinicalTrials.gov |
| NCT04536337 | A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics a… | Phase1 | Chronic Hepatitis B | Completed | 2020-10-22 | 2025-06-16 | ClinicalTrials.gov |
| NCT04485663 | A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics a… | Phase1 | Chronic Hepatitis B | Terminated | 2020-08-17 | 2022-03-08 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Pevifoscorvir Sodium (ALG-000184) | Other | Phase PHASE1 | Chronic Hepatitis B Infections | COMPLETED | NCT07342868 |
| Pevifoscorvir Sodium (ALG-000184) | Other | Phase PHASE1 | Chronic Hepatitis B Infection | COMPLETED | NCT07342881 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B Infection | ACTIVE_NOT_RECRUITING | NCT06963710 |
| ALG-000184 | Other | Phase PHASE2 | Chronic Hepatitis B Infection | ACTIVE_NOT_RECRUITING | NCT06963710 |
| ALG-097558 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06568861 |
| ALG-097558 | Other | Phase PHASE1 | COVID 19 | COMPLETED | NCT06698549 |
| ALG-097558 | Other | Phase PHASE1 | COVID 19 | COMPLETED | NCT06698549 |
| ALG-097558 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06568861 |
| ALG-097558 | Other | Phase PHASE1 | COVID 19 | COMPLETED | NCT06698549 |
| ALG-097558 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06568861 |
| ALG-097558 | Other | Phase PHASE1 | COVID 19 | COMPLETED | NCT06698549 |
| ALG-097558 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06568861 |
| ALG-097558 | Other | Phase PHASE1 | COVID 19 | COMPLETED | NCT06698549 |
| ALG-097558 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06568861 |
| ALG-097558 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06568861 |
| ALG-097558 | Other | Phase PHASE1 | COVID 19 | COMPLETED | NCT06698549 |
| ALG-097558 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06568861 |
| ALG-097558 | Other | Phase PHASE1 | COVID 19 | COMPLETED | NCT06698549 |
| ALG-097558 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06568861 |
| ALG-097558 | Other | Phase PHASE1 | COVID 19 | COMPLETED | NCT06698549 |
| ALG-097558 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06568861 |
| ALG-097558 | Other | Phase PHASE1 | COVID 19 | COMPLETED | NCT06698549 |
| ALG-097558 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06568861 |
| ALG-097558 | Other | Phase PHASE1 | COVID 19 | COMPLETED | NCT06698549 |
| ALG-097558 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06568861 |
| ALG-097558 | Other | Phase PHASE1 | COVID 19 | COMPLETED | NCT06698549 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06191991 |
| ALG-055009 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06191991 |
| Atorvastatin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06191991 |
| Placebo | Other | Phase PHASE1 | Chronic Hepatitis B | TERMINATED | NCT04485663 |
| ALG-010133 | Other | Phase PHASE1 | Chronic Hepatitis B | TERMINATED | NCT04485663 |
| Placebo | Other | Phase PHASE1 | Chronic Hepatitis B | TERMINATED | NCT05001022 |
| ALG-020572 | Other | Phase PHASE1 | Chronic Hepatitis B | TERMINATED | NCT05001022 |
| Placebo | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT05090111 |
| ALG-055009 | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT05090111 |
| Placebo | Other | Phase PHASE1 | Chronic Hepatitis B | TERMINATED | NCT05561530 |
| ALG-125755 | Other | Phase PHASE1 | Chronic Hepatitis B | TERMINATED | NCT05561530 |
| ALG-000184 | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT06672900 |
| Itraconazole (Sporanox) | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT06672900 |
| Carbamazepine | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT06672900 |
| Placebo | Other | Phase PHASE2 | NASH | COMPLETED | NCT06342947 |
| ALG-055009 | Other | Phase PHASE2 | NASH | COMPLETED | NCT06342947 |
| ALG-097558 in tablet formulation | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05840952 |
| ALG-097558 in solution formulation | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05840952 |
| Carbamazepine | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05840952 |
| Itraconazole | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05840952 |
| Midazolam | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05840952 |
| Placebo | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05840952 |
| ALG-097558 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05840952 |
| ALG-055009 | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06959888 |
| ALG-097558 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06568861 |
| ALG-097558 | Other | Phase PHASE1 | COVID 19 | COMPLETED | NCT06698549 |
| Entecavir | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04536337 |
| Placebo | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04536337 |
| ALG-000184 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04536337 |
| Pevifoscorvir Sodium (ALG-000184) | Other | Phase PHASE1 | Chronic Hepaititis B Infections | RECRUITING | NCT07342868 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| ALG-000184 | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| Pevifoscorvir Sodium (ALG-000184) | Other | Phase PHASE1 | Chronic Hepatitis B Infection | RECRUITING | NCT07342881 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| ALG-000184 | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| ALG-000184 | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| ALG-000184 | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| ALG-000184 | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| ALG-000184 | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| ALG-000184 | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| ALG-000184 | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| ALG-000184 | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| ALG-000184 | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| ALG-000184 | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| ALG-000184 | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |
| ALG-000184 | Other | Phase PHASE2 | Chronic Hepatitis B Infection | RECRUITING | NCT06963710 |